Advanced Filters
noise
Found 64,778 clinical trials
S Sol Fernández-Gonzalo, PhD

Rehabilitation Gaming System for Intensive Care Units

Admission to an Intensive Care Unit (ICU) is a potentially traumatic experience for a mentally vulnerable person. Beyond the stress and anxiety associated with the ICU environment and medical procedures, survivors of critical illness are at risk of developing cognitive and psychological sequelae related to Post-Intensive Care Syndrome (PICS). These …

18 years of age All Phase N/A
N Nour A Elsherbeny, Bachelor of Pharmacy

Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

Parkinson's disease (PD) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein protein aggregates. Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, will be studied for its neuroprotective effects in PD.

45 - 65 years of age All Phase 2
H Hanna Molla

Mood Effects of Serotonin Agonists: Depression

This study will examine the effect of a low dose of the 5HT2A agonist LSD (26 µg), compared to placebo, on acute and protracted mood states in individuals with depression. The investigators will assess the relationship between mood-related symptoms and EEG as a neurophysiological marker.

18 - 40 years of age All Phase N/A
S Sydney Whittaker, BS

Initial Resuscitation for Acute Kidney Injury in Cirrhosis

The goal of this interventional study is to evaluate two strategies for how to provide intravenous (IV) fluids for treating patients with acute kidney injury (AKI) in cirrhosis. The main question it aims to answer is: what is the safety, efficacy, and feasibility of providing a recommendation to use a …

18 years of age All Phase N/A
K Kun Chen, Doctor

Treatment of Moderate to Severe Plaque Psoriasis

To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis, as well as the PK and PD characteristics of multiple doses

18 - 70 years of age All Phase 2
H Henrik M Roager, PhD

Why Calories Are Not the Same - a Gut Explanation?

The aim of this study is to understand how the gut microbiome influences how much dietary energy humans excrete via feces. This study is based on the hypothesis that levels of methane in exhaled breath represent two different gut microbiome community structures, and therefore influence fecal energy excretion differently. Moreover, …

18 - 65 years of age All Phase N/A
C Courtney Schepel

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

The purpose of this research is to see how personal financial burden (financial toxicity) related to cancer affects the overall health and quality of life by evaluating the impact of systematic financial navigation in addition to standard financial distress interventions during cancer treatment.

18 - 64 years of age All Phase N/A
E Elif Simay KOÇ, 2

Use of Hand Puppets and Image Watching and Coloring Books for Children in During Blood Collection Procedures

The aim of this study was to compare a hand puppet with image viewing and a coloring book for children in reducing children's pain and fear during blood collection.

3 - 6 years of age All Phase N/A

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR). The ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate …

18 years of age All Phase 1
J Jeffrey Motter, PhD

Olfactory Training in Mild Cognitive Impairment

Sense of smell tends to decline in individuals with early Alzheimer's disease, typically earlier than when other senses and thinking abilities begin to decline. Memory for new odors is particularly diminished in these individuals. Existing treatments for AD do not improve these symptoms. A targeted treatment for improving sense of …

55 - 89 years of age All Phase N/A

Simplify language using AI